Kathrin Klein

Title: Kathrin Klein: Innovator in Biotransformation and Sugar Substitute Technologies

Introduction

Kathrin Klein is a prominent inventor based in Stuttgart, Germany. She has made significant contributions to the fields of biotransformation and the development of non-cariogenic sugar substitutes. With a total of six patents to her name, her work has the potential to impact both medical treatments and food industries.

Latest Patents

One of her latest patents is a method for determining the predisposition of a patient to changed biotransformation and to the development of undesired drug effects in a treatment involving atorvastatin. This method involves identifying the presence of at least one single nucleotide polymorphism (SNP) in the UGT1A3 gene and/or an increased UGT1A3 gene expression in a biological sample from the patient. Additionally, she has developed a process for the preparation of acariogenic sugar substitutes, which includes sucrose isomerases and DNA sequences that code for these enzymes.

Career Highlights

Kathrin has worked with Sudzucker Aktiengesellschaft and Sudzucker Aktiengesellschaft Mannheim/Ochsenfurt, where she has applied her expertise in biochemistry and genetics to advance innovative solutions in her field. Her work has garnered attention for its practical applications in both healthcare and food technology.

Collaborations

Kathrin has collaborated with notable professionals in her field, including Ralf Mattes and Markwart Kunz. These partnerships have allowed her to enhance her research and expand the impact of her inventions.

Conclusion

Kathrin Klein is a trailblazer in her field, with a focus on improving patient outcomes and creating healthier food alternatives. Her innovative patents and collaborations highlight her commitment to advancing science and technology.